GLP-1 drugsReview

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal

The paper

Eugenia Pedagogos, Roger Chen, Adam J. Nelson,

Sunil V. Badve, Roy Rasalam,

Richard J. MacIsaac

The University of Melbourne · St Vincent's Hospital Melbourne

Internal Medicine Journal · 30 Sep 2026

doi.org/10.1111/imj.70647 PubMed 42813318

Semaglutide curbs kidney vascular resistance and fibrosis
Nature Medicine · 4 Oct 2026
GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026